Seeking Alpha

Seeking Alpha Portfolio App for iPad

Prohost Biotech

Prohost Biotech picture

Prohost Biotech

Profile

1,013 Followers

Send Message

View as an RSS Feed

View Prohost Biotech's Articles BY TICKER:

The True Value Of Seattle Genetics
on Thu, May 9 • SGEN • 7 Comments
Sarepta: What's Going On?
on Wed, Apr 17 • SRPT • 3 Comments
ImmunoGen Offers New Hope For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Cancers
on Sun, Apr 14 • IMGN • 6 Comments
A Quick Response To Ariad's Conference Call
on Fri, Apr 5 • ARIA • 20 Comments
Northwest Biotherapeutics: An Example Of Reform In The Drug Approval Process
on Wed, Mar 6 • NWBO • 7 Comments
Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?
on Wed, Feb 6 • ELN, BIIB • 2 Comments
Isis: FDA Approval Of Kynamro Promises A Bright Future For Company
on Fri, Feb 1 • SNY, ALNY, SRPT • 24 Comments
XOMA: Will The Love-Hate Marriage With Investors Finally End Up In A Stable Relationship?
on Wed, Jan 16 • XOMA • 4 Comments
Theravance: Tempting To Investors As Well As Partners
on Tue, Jan 8 • GSK, THRX • Comment!
Ariad: Iclusig's Approval Deserves Honoring The Developer, Not Bashing Its Stock
on Tue, Dec 18, 2012 • ARIA • 3 Comments
The Road Toward Far-Reaching Therapeutics Through Illumina, Sarepta
on Tue, Dec 4, 2012 • ILMN, SRPT, EXEL • 3 Comments
ImmunoGen's Press Release Is More Than Mere News
on Tue, Dec 4, 2012 • IMGN • 3 Comments
ChemoCentryx: A Leader Of A New Line Of Investigational Treatments
on Mon, Oct 8, 2012 • GSK, CCXI • Comment!
Biotech: On The Way To Meeting Highly Ambitious Expectations
on Mon, Sep 10, 2012 • ALNY, ISIS, SRPT • 1 Comment
ImmunoGen: 2 Pieces Of Good News In 1 Announcement
on Mon, Aug 27, 2012 • RHHBY.OB, IMGN • 6 Comments
Why A Sell-Off Among The Best Oncology Biotech Firms?
on Wed, Aug 15, 2012 • INCY, IMGN, AVEO • 12 Comments
Pluristem: 2 Cases Enough To Raise Investor Curiosity?
on Mon, Aug 6, 2012 • PSTI • 10 Comments
An Assault On Vertex, Enthusiasm Building Around Xoma
on Fri, Jul 6, 2012 • VRTX, XOMA • 7 Comments
Pharmacyclics: Product Pipeline Overshadows Stock Market Influence
on Wed, Jun 20, 2012 • PCYC • 2 Comments
ImmunoGen Has Good News To Share
on Tue, Jun 5, 2012 • IMGN, ROG, EXEL • 3 Comments
Aveo And Exelixis At The Finish Line
on Thu, May 31, 2012 • AVEO, EXEL • 12 Comments
Redefining The Meaning Of 'Creating Shareholder Value' In Biotech
on Tue, May 15, 2012 • VRTX, REGN, INCY • 2 Comments
Vertex: Well-Equipped To Own The Future
on Tue, May 8, 2012 • VRTX • 4 Comments
Illumina And Human Genome: Reasons For Rejections Of Takeovers
on Mon, Apr 23, 2012 • ILMN, GSK • Comment!
Affymax Poised To Take On Amgen?
on Tue, Apr 3, 2012 • AFFY, ALNY, AMGN • 11 Comments
Ariad's mTOR And The FDA Committee
on Wed, Mar 21, 2012 • ARIA • Comment!
Ariad Prepares For FDA Committee
on Tue, Mar 20, 2012 • ARIA, NVS, PFE • 4 Comments
Agenus Continues to Outperform
on Fri, Mar 16, 2012 • AGEN, GSK • 1 Comment
Addressing Vertex / Gilead Confusion
on Thu, Mar 1, 2012 • VRTX, GILD • 3 Comments
Pharmacyclics: When The Power Of A Pipeline Overshadows The Market's Influence On Value
on Fri, Feb 24, 2012 • PCYC, JNJ • 1 Comment
Illumina, Roche And Fairness
on Thu, Feb 9, 2012 • RHHBY.OB, VRTX, ISIS • 3 Comments
Xoma's New Plans Bring Hesitant Hope
on Wed, Jan 25, 2012 • XOMA • 3 Comments